|
|
 |
 |
| |
 Printable version |
Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod |
European Journal of Dermatology. Volume 12, Number 6, 569-72, November - December 2002, Thérapie
|
 Free Article
|
Author(s) : Eggert STOCKFLETH, Claas ULRICH, Axel HAUSCHILD, Stephan LISCHNER, Thomas MEYER, Enno CHRISTOPHERS |
Summary : Gorlin-Goltz syndrome, also referred to as naevoid basal cell carcinoma syndrome (NBCCS), is an autosomal dominant skin disease with complete penetrance and inconstancy of the four major findings: multiple naevoid basal cell carcinomas (BCCs), pits on palms and soles, skeletal abnormalities (for example, jaw cysts), and ectopic calcification. The treatment of multiple BCCs is still a matter of debate. We report three cases of multiple BCCs in Gorlin-Goltz syndrome treated with topical 5% imiquimod cream, an immune response modifier. Patients were successfully cleared of BCCs after treatment for 6-8 weeks. Histologically no apparent signs of BCC-persistence could be detected and no recurrences were detected during the 12 month follow up period. |
Keywords : Gorlin-Goltz syndrome, basal cell carcinoma, immune response modifier, imiquimod. |
|
